Argos Therapeutics (FRA:77AA) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Sep. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Argos Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Argos Therapeutics's net issuance of preferred for the three months ended in Sep. 2018 was €0.00 Mil. The number is 0, which means that Argos Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Argos Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Sep. 2018 was €0.00 Mil.

Argos Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Argos Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argos Therapeutics Net Issuance of Preferred Stock Chart

Argos Therapeutics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

34.61

Argos Therapeutics Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Argos Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Argos Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Argos Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Argos Therapeutics (FRA:77AA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argos Therapeutics Inc (FRA:77AA) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

4233 Technology Drive, Durham, NC, USA, 27704

Website

http://www.argostherapeutics.com

Argos Therapeutics Inc is a biopharmaceutical company. It is engaged in the development and commercialization of immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis.

Argos Therapeutics (FRA:77AA) Headlines

No Headlines